Connect with us

News

Women’s health start-up Daye expands diagnostic tampon to include STI screening

More than half of Brits admit they have never been for a sexual health check

Published

on

The UK gynaecological health start-up Daye has expanded its tampon-based vaginal microbiome screening kit to include STI screening. 

The tampon-based at-home STI screening kit is hoped to help speed up diagnosis and treatment, particularly among patient groups who are anxious or embarrassed about getting a test.

It uses PCR testing technology to allow women and assigned female at birth (AFAB) individuals to test for chlamydia, gonorrhoea, trichomonas, mycoplasma and ureaplasma from home.

The launch follows clinical trials with 600 patients. The samples will be analysed in a UKAS-accredited lab, following CQC-approved screening methodologies using a PCR-based, CE marked diagnostic assay.

As part of the service, Daye will also provide personalised aftercare, including prescription treatments such as antibiotics and antivirals, and consultations with sexual health nurses, gynaecologists and fertility specialists.

There has been a 24 per cent increase in sexually transmitted infections compared to the previous year, according to the UK Health Security Agency, with women being statistically more at risk than men due to the vaginal physiology.

Despite this, fewer people are getting tested for STIs, with over half of Brits admitting they have never been for a sexual health check.

STIs still carry a lot of stigma, yet are often treatable if caught in time. However, testing is still thought to be embarrassing and uncomfortable.

Low rates of testing mean that many women and AFAB individuals may be unaware they have an STI as 70 per cent of them are asymptomatic.

However, untreated STIs pose risks to long-term health and fertility. Chlamydia and gonorrhoea are two of the leading preventable causes of infertility and ectopic pregnancies.

Mother-to-child transmission of STIs can result in stillbirth, neonatal death, low birth weight and other health complications. Untreated STIs can also lead to chronic pelvic pain and pelvic inflammatory disease.

“Despite living in a world where over a million people get an STI every day, STI testing has chronically low rates post COVID-19, and as a result, many women and AFAB individuals could have an infection unknowingly because they have no symptoms,” said Valentina Milanova, founder of Daye.

“Our STI diagnostic tampon makes STI testing extremely easy, comfortable and discrete.

“We hope our approach will end the ‘STIgma’, revolutionise STI testing and lead to a dramatic uptick in the number of women getting checked, helping them protect their long-term health and fertility.”

According to Daye, the test uses PCR technologies which are able to detect even trace amounts of genetic material from pathogens.

The specificity of PCRs, the company argues, ensures that false-positive results are reduced, providing a more reliable diagnosis and simultaneously detecting multiple pathogens in a single sample.

Dr Michelle Tempest, lecturer in medical law and ethics at Cambridge Medical School and former NHS hospital doctor, said: “Daye’s STI diagnostic tampon is redefining STI testing by allowing women to take control of their sexual health in a non-invasive way in the comfort of their own homes.

“The company’s innovative use of a tampon for screening is supported by various studies that show that tampons are capable of collecting an equivalent or superior sample to a swab.”

News

Labcorp launches screening test to identify preeclampsia risk sooner

The new screening tool is capable of assessing the risk of preeclampsia sooner, the test maker says

Published

on

Labcorp has launched a screening test that can assess the risk of preeclampsia before 34 weeks of pregnancy.

Preeclampsia is a high blood pressure disorder that can develop during pregnancy or postpartum and is a leading cause of maternal morbidity and mortality worldwide.

Roughly one in 25 pregnancies in the US is affected by preeclampsia, which poses an even greater risk for non-Hispanic black women, who experience the condition at a 60 per cent higher rate compared to white women.

In January, Labcorp announced the launch and availability of an FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia during the second and third trimesters.

The first trimester test uses four early pregnancy biomarkers to provide a risk assessment with up to 90 per cent sensitivity, nearly twice the sensitivity of assessing typical maternal history or biophysical factors alone.

According to Labcorp, the test results provide risk identification earlier than traditional symptoms, such as hypertension or protein in the urine, which tend to develop around 20 weeks gestation.

Eleni Tsigas, chief executive officer of the Preeclampsia Foundation, said: “Our organisation celebrates this innovative new test offering.

“Research shows that patients and providers want access to more tools that better predict progression to preeclampsia, especially for those patients with low- to average-risk or those with first-time pregnancies for whom there is some uncertainty.”

Dr Brian Caveney, chief medical and scientific officer at Labcorp, added: “Labcorp is committed to advancing maternal and foetal health through innovative diagnostic and screening solutions.

“This new first trimester blood test is another significant milestone in our mission to improve health and improve lives. By giving healthcare providers another tool to assess preeclampsia risk in their pregnant patients with objective biomarkers, we’re helping to advance prenatal care and improve outcomes for mothers and their babies.”

Continue Reading

News

People with HIV can be sperm and egg donors

A change in law will allow people with non-transmissible HIV in the UK to donate gametes to partners

Published

on

Same-sex couples with non-transmissible HIV will now be able to donate eggs or sperm and become parents.

People with HIV will able to donate their sperm or eggs to their partners, as the law in the UK is updated.

The Human Fertilisation and Embryology Act will be amended via a statutory instrument to allow people with non-transmissible HIV – with a viral load low enough not to pass on – to donate eggs or sperm, known as gametes, as part of fertility treatment to their partners.

Under current rules on IVF, only a male partner with HIV can give their sperm to their female partner and not to anyone else.

The law change will also eliminate extra screening costs for female same-sex couples undertaking reciprocal IVF treatment.

The government says this is part of wider work to improve access to IVF for everyone and ensure same-sex couples have the same rights as a man and woman when trying to conceive.

“These changes will allow more people to fulfil their dream of becoming parents,” said UK health minister, Maria Caulfield.

“We have changed the law to ensure equality for people living with HIV when accessing IVF, allowing them to donate their eggs and sperm.

“In addition, the change will allow female same-sex couples to access IVF with no extra screening costs, the same as heterosexual couples.”

She added: “These changes will help create a fairer system by removing barriers to accessing fertility care as we have set out in the Women’s Health Strategy.”

The changes to the law will allow people with HIV to donate their gametes to family, friends and known recipients.

The regulations include an updated definition of partner donation to enable female same-sex couples wishing to donate eggs to each other to undergo the same testing requirements as heterosexual couples.

Under current rules, female same-sex couples hoping to conceive via reciprocal IVF must first go through screening for syphilis and genetic screening, such as cystic fibrosis, which can cost over £1,000, while heterosexual couples do not need to undergo this screening.

Julia Chain, chair of the Human Fertilisation and Embryology Authority (HFEA), said: “The HFEA welcomes the news that legislation regarding partner donation in relation to reciprocal IVF, and gamete donation from those who have HIV with an undetectable viral load, has now been proposed in Parliament.

“Fertility treatment is helping more people than ever to create their family, and everyone undergoing fertility treatment should be treated fairly.

“For known donation from individuals with undetectable HIV, we anticipate that the first clinics may be able to begin to offer this treatment around 3 months following a change in the law.

“We encourage any patients or donors who may be affected by these changes to visit the HFEA website to find out free and impartial information, including about how to choose a fertility clinic.”

Minister for equalities, Stuart Andrew MP, added: “Treatment for HIV has improved significantly, saving countless lives, but the stigma surrounding it persists – a stigma which often prevents people from getting tested and seeking treatment.

“These changes will help to reduce that stigma, making it clear that people with HIV can live full and happy lives. I am delighted by these changes which will enable more people to experience the joy of becoming parents.”

Continue Reading

News

Portfolia invests total of US$65m into women’s health companies

The platform has invested in 47 femtech start-ups to date

Published

on

Trish Costello, founder and CEO of Portfolia

The US venture investing platform Portfolia has announced it has invested a total of US$65m into women’s health companies and solutions.

Portfolia aims to create, educate and support the largest community of women investors in the world.

The company says it was amongst the first to recognise the “immense” potential of women’s wealth, with women’s health at the forefront.

To date, Portfolia has made investments in 112 companies with 47 of those women’s health companies being femtech and active aging specific.

Some of these include Madison Reed, Maven, Everly Health, Bone Health, Veana, Your Choice, Future Family, Willow, Hey Jane, Lighthouse Pharma, L-Nutra and JoyLux.

The total companies Portfolia has invested in are estimated to serve over 102 million customers in 115 countries worldwide.

These companies have a combined value of over US$17bn, with over US$1bn in revenue and 10,000 employees worldwide.

According to Portfolia, almost 70 per cent of these businesses are led by female CEOs, and 49 per cent are led by BIPOC individuals.

“At Portfolia, we believe in the power of activating our wealth for returns and impact,” said Trish Costello, founder and CEO of Portfolia.

“Today, women in the United States have unprecedented access to wealth – with over US$25tn of wealth in the US and almost 50 per cent of it owned by women.

“This wealth is power – power to create financial change and invest in the companies and businesses that matter to us and meet our needs/desires.”

She added: “Our commitment goes beyond traditional venture capital – we’re pioneering change, saving lives, and creating opportunities for all, while creating the most powerful community of women investors globally, and the first to activate our wealth to shape the future of healthcare.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.